{"id":"https://openalex.org/W2789912955","doi":"https://doi.org/10.1128/aac.02580-17","title":"A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)","display_name":"A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)","publication_year":2018,"publication_date":"2018-03-12","ids":{"openalex":"https://openalex.org/W2789912955","doi":"https://doi.org/10.1128/aac.02580-17","mag":"2789912955","pmid":"https://pubmed.ncbi.nlm.nih.gov/29530858","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5923167"},"language":"en","primary_location":{"id":"doi:10.1128/aac.02580-17","doi":"https://doi.org/10.1128/aac.02580-17","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.02580-17","pdf_url":"http://eprints.whiterose.ac.uk/134866/9/A%20phase%203%20randmoised%20double%20blind%20multicentre%20study.pdf","source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://eprints.whiterose.ac.uk/134866/9/A%20phase%203%20randmoised%20double%20blind%20multicentre%20study.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057825659","display_name":"Thomas L Holland","orcid":"https://orcid.org/0000-0001-7745-9010","observed_orcids":["https://orcid.org/0000-0001-7745-9010"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas L. Holland","raw_affiliation_strings":["Duke University Medical Center, Durham, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, North Carolina, USA","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110473005","display_name":"William D. O\u2019Riordan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William O'Riordan","raw_affiliation_strings":["eStudySites, San Diego, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"eStudySites, San Diego, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012994063","display_name":"Alison J. McManus","orcid":"https://orcid.org/0000-0003-1330-0961","observed_orcids":["https://orcid.org/0000-0003-1330-0961"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alison McManus","raw_affiliation_strings":["eStudySites, San Diego, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"eStudySites, San Diego, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058130405","display_name":"Elliot Shin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elliot Shin","raw_affiliation_strings":["eStudySites, San Diego, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"eStudySites, San Diego, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047033317","display_name":"Ali Borghei","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142143","display_name":"Los Angeles Clinical Trials","ror":"https://ror.org/04eme8h94","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210142143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ali Borghei","raw_affiliation_strings":["Long Beach Clinical Trials, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Long Beach Clinical Trials, Los Angeles, California, USA","institution_ids":["https://openalex.org/I4210142143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113451778","display_name":"Thomas M. File","orcid":"https://orcid.org/0009-0009-6080-467X","observed_orcids":["https://orcid.org/0009-0009-6080-467X"]},"institutions":[{"id":"https://openalex.org/I1294639003","display_name":"Summa Health System","ror":"https://ror.org/03p6fpw74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1294639003"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas M. File","raw_affiliation_strings":["Summa Health, Akron, Ohio, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Summa Health, Akron, Ohio, USA","institution_ids":["https://openalex.org/I1294639003"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027928189","display_name":"Mark H. Wilcox","orcid":"https://orcid.org/0000-0002-4565-2868","observed_orcids":["https://orcid.org/0000-0002-4565-2868"]},"institutions":[{"id":"https://openalex.org/I130828816","display_name":"University of Leeds","ror":"https://ror.org/024mrxd33","country_code":"GB","type":"education","lineage":["https://openalex.org/I130828816"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mark H. Wilcox","raw_affiliation_strings":["Leeds Teaching Hospitals & University of Leeds, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leeds Teaching Hospitals & University of Leeds, Leeds, United Kingdom","institution_ids":["https://openalex.org/I130828816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100752902","display_name":"Anton\u00ed Torres","orcid":"https://orcid.org/0000-0002-8643-2167","observed_orcids":["https://orcid.org/0000-0002-8643-2167","https://orcid.org/0000-0002-5470-2978"]},"institutions":[{"id":"https://openalex.org/I4210099160","display_name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias","ror":"https://ror.org/0119pby33","country_code":"ES","type":"facility","lineage":["https://openalex.org/I2801357902","https://openalex.org/I4210099160","https://openalex.org/I4210115082","https://openalex.org/I4387152914"]},{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]},{"id":"https://openalex.org/I71999127","display_name":"Universitat de Barcelona","ror":"https://ror.org/021018s57","country_code":"ES","type":"education","lineage":["https://openalex.org/I71999127"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Antoni Torres","raw_affiliation_strings":["Centro de Investigaci\u00f3n Biomedica En Red-Enfermedades Respiratorias, Barcelona, Spain","Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions August Pi I Sunyer, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Investigaci\u00f3n Biomedica En Red-Enfermedades Respiratorias, Barcelona, Spain","institution_ids":["https://openalex.org/I4210099160"]},{"raw_affiliation_string":"Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut d'Investigacions August Pi I Sunyer, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097","https://openalex.org/I71999127"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010679786","display_name":"Matthew Dryden","orcid":"https://orcid.org/0000-0002-8967-169X","observed_orcids":["https://orcid.org/0000-0002-8967-169X"]},"institutions":[{"id":"https://openalex.org/I312843336","display_name":"Hampshire Hospitals NHS Foundation Trust","ror":"https://ror.org/04shzs249","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I312843336"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Dryden","raw_affiliation_strings":["Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom","institution_ids":["https://openalex.org/I312843336"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084249121","display_name":"Thomas P. Lodise","orcid":"https://orcid.org/0000-0002-4730-0655","observed_orcids":["https://orcid.org/0000-0002-4730-0655"]},"institutions":[{"id":"https://openalex.org/I365282","display_name":"Albany College of Pharmacy and Health Sciences","ror":"https://ror.org/014hfaw95","country_code":"US","type":"education","lineage":["https://openalex.org/I365282"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Lodise","raw_affiliation_strings":["Albany College of Pharmacy and Health Sciences, Albany, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Albany College of Pharmacy and Health Sciences, Albany, New York","institution_ids":["https://openalex.org/I365282"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Toyoko Oguri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I60638368","display_name":"Covance (United States)","ror":"https://ror.org/02hhsqf45","country_code":"US","type":"company","lineage":["https://openalex.org/I60638368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Toyoko Oguri","raw_affiliation_strings":["Covance, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I60638368"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059959498","display_name":"G. Ralph Corey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Ralph Corey","raw_affiliation_strings":["Duke University Medical Center, Durham, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, North Carolina, USA","institution_ids":["https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101832222","display_name":"Patrick McLeroth","orcid":"https://orcid.org/0000-0002-2088-2114","observed_orcids":["https://orcid.org/0000-0002-2088-2114"]},"institutions":[{"id":"https://openalex.org/I60638368","display_name":"Covance (United States)","ror":"https://ror.org/02hhsqf45","country_code":"US","type":"company","lineage":["https://openalex.org/I60638368"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick McLeroth","raw_affiliation_strings":["Covance, Princeton, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I60638368"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001873752","display_name":"Rajesh Shukla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140002","display_name":"Motif BioSciences (United States)","ror":"https://ror.org/04815fk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140002"]},{"id":"https://openalex.org/I4402554120","display_name":"Rutgers New Jersey Medical School","ror":"https://ror.org/014ye1258","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4402554120"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajesh Shukla","raw_affiliation_strings":["Motif BioSciences, New York, New York, USA, and Rutgers New Jersey Medical School, Newark, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Motif BioSciences, New York, New York, USA, and Rutgers New Jersey Medical School, Newark, New Jersey, USA","institution_ids":["https://openalex.org/I4210140002","https://openalex.org/I4402554120"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016570350","display_name":"David B. Huang","orcid":"https://orcid.org/0000-0001-8228-7911","observed_orcids":["https://orcid.org/0000-0001-8228-7911","https://orcid.org/0000-0002-8342-3193"]},"institutions":[{"id":"https://openalex.org/I4210140002","display_name":"Motif BioSciences (United States)","ror":"https://ror.org/04815fk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140002"]},{"id":"https://openalex.org/I4402554120","display_name":"Rutgers New Jersey Medical School","ror":"https://ror.org/014ye1258","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4402554120"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David B. Huang","raw_affiliation_strings":["Motif BioSciences, New York, New York, USA, and Rutgers New Jersey Medical School, Newark, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Motif BioSciences, New York, New York, USA, and Rutgers New Jersey Medical School, Newark, New Jersey, USA","institution_ids":["https://openalex.org/I4210140002","https://openalex.org/I4402554120"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.534,"has_fulltext":true,"cited_by_count":40,"citation_normalized_percentile":{"value":0.95400168,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"62","issue":"5","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.9092000126838684,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.03700000047683716,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11153","display_name":"Streptococcal Infections and Treatments","score":0.020099999383091927,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iclaprim","display_name":"iclaprim","score":1.0},{"id":"https://openalex.org/keywords/vancomycin","display_name":"vancomycin","score":0.9940000176429749},{"id":"https://openalex.org/keywords/acute-bacterial-skin-and-skin-structure-infections","display_name":"acute bacterial skin and skin structure infections","score":0.9959999918937683},{"id":"https://openalex.org/keywords/gram-positive-bacterial-infections","display_name":"Gram-positive bacterial infections","score":0.7879999876022339},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.847000002861023},{"id":"https://openalex.org/keywords/lesion-size-reduction","display_name":"lesion size reduction","score":0.9070000052452087},{"id":"https://openalex.org/keywords/intravenous-antibiotics","display_name":"intravenous antibiotics","score":0.8939999938011169},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.6759999990463257}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7847986221313477},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.7552610039710999},{"id":"https://openalex.org/C2778980435","wikidata":"https://www.wikidata.org/wiki/Q424027","display_name":"Vancomycin","level":4,"score":0.6303321123123169},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5153514742851257},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5072081089019775},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4598601162433624},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.430730938911438},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4286736249923706},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4203530550003052},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37218180298805237},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3255253732204437},{"id":"https://openalex.org/C2779489039","wikidata":"https://www.wikidata.org/wiki/Q188121","display_name":"Staphylococcus aureus","level":3,"score":0.14091548323631287},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.1007428765296936},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0726509690284729},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006094","descriptor_name":"Gram-Positive Bacteria","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006094","descriptor_name":"Gram-Positive Bacteria","qualifier_ui":"Q000472","qualifier_name":"pathogenicity","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017192","descriptor_name":"Skin Diseases, Bacterial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D017192","descriptor_name":"Skin Diseases, Bacterial","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":false},{"descriptor_ui":"D061605","descriptor_name":"Administration, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1128/aac.02580-17","doi":"https://doi.org/10.1128/aac.02580-17","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.02580-17","pdf_url":"http://eprints.whiterose.ac.uk/134866/9/A%20phase%203%20randmoised%20double%20blind%20multicentre%20study.pdf","source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5143691","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5923167","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5923167","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5923167","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:29530858","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29530858","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:eprints.whiterose.ac.uk:134866","doi":null,"is_oa":false,"landing_page_url":"http://eprints.whiterose.ac.uk/134866/9/A%20phase%203%20randmoised%20double%20blind%20multicentre%20study.pdf","pdf_url":"http://eprints.whiterose.ac.uk/134866/9/A%20phase%203%20randmoised%20double%20blind%20multicentre%20study.pdf","source":{"id":"https://openalex.org/S4306400854","display_name":"White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2800616092","host_organization_name":"White Rose University Consortium","host_organization_lineage":["https://openalex.org/I2800616092"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1128/aac.02580-17","doi":"https://doi.org/10.1128/aac.02580-17","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.02580-17","pdf_url":"http://eprints.whiterose.ac.uk/134866/9/A%20phase%203%20randmoised%20double%20blind%20multicentre%20study.pdf","source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2789912955.pdf","grobid_xml":"https://content.openalex.org/works/W2789912955.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1902652724","https://openalex.org/W1976915176","https://openalex.org/W2064860136","https://openalex.org/W2071948555","https://openalex.org/W2106793787","https://openalex.org/W2116814997","https://openalex.org/W2119542781","https://openalex.org/W2131316809","https://openalex.org/W2136609531","https://openalex.org/W2142827309","https://openalex.org/W2155800098","https://openalex.org/W2194639874","https://openalex.org/W2411016089","https://openalex.org/W2436281676","https://openalex.org/W2610895230","https://openalex.org/W2765178452","https://openalex.org/W2771486808","https://openalex.org/W2775563532","https://openalex.org/W2778606863"],"related_works":["https://openalex.org/W2778606863","https://openalex.org/W2752713307","https://openalex.org/W2804406807","https://openalex.org/W3010816592","https://openalex.org/W2940825000","https://openalex.org/W4295935779","https://openalex.org/W2799714015","https://openalex.org/W2158190550","https://openalex.org/W2782076686","https://openalex.org/W2896658653"],"abstract_inverted_index":{"Iclaprim":[0,158],"is":[1],"a":[2,27,88],"novel":[3],"diaminopyrimidine":[4],"antibiotic":[5],"that":[6,96],"may":[7,201],"be":[8,52,202,215],"an":[9,203],"effective":[10],"and":[11,20,43,190,205],"safe":[12,206],"treatment":[13,185,207],"for":[14,79,183,208],"serious":[15],"skin":[16,42,44,189,191,209],"infections.":[17,193],"The":[18,84],"safety":[19],"effectiveness":[21],"of":[22,67,71,108,110,124,133,135,186,197],"iclaprim":[23,60,172,200],"were":[24,57,73],"assessed":[25],"in":[26,91,113,177],"global":[28],"phase":[29,179],"3,":[30],"double-blind,":[31],"randomized,":[32],"active-controlled":[33],"trial.":[34],"Six":[35],"hundred":[36],"thirteen":[37],"adults":[38],"with":[39,95,162],"acute":[40,187],"bacterial":[41,188],"structure":[45,192],"infections":[46,210],"(ABSSSIs)":[47],"suspected":[48,211],"or":[49,63,212],"confirmed":[50,213],"to":[51,54,59,81,102,120,149,175,214,217],"due":[53,216],"Gram-positive":[55,218],"pathogens":[56],"randomized":[58,119],"(80":[61],"mg)":[62],"vancomycin":[64,138,176],"(15":[65],"mg/kg":[66],"body":[68],"weight),":[69],"both":[70],"which":[72],"administered":[74],"intravenously":[75],"every":[76],"12":[77],"h":[78,104],"5":[80],"14":[82],"days.":[83],"primary":[85,128,141],"endpoint":[86,142],"was":[87,159,173],"\u226520%":[89],"reduction":[90],"lesion":[92],"size":[93],"compared":[94],"at":[97,100,225],"the":[98,106,114,153,184,195],"baseline":[99],"48":[101],"72":[103],"after":[105],"start":[107],"administration":[109],"study":[111],"drug":[112],"intent-to-treat":[115],"population.":[116],"Among":[117],"patients":[118],"iclaprim,":[121],"78.3%":[122],"(231":[123],"295)":[125],"met":[126,139,152],"this":[127,140,178],"endpoint,":[129],"whereas":[130],"76.7%":[131],"(234":[132],"305)":[134],"those":[136],"receiving":[137],"(difference,":[143],"1.58%;":[144],"95%":[145],"confidence":[146],"interval,":[147],"-5.10%":[148],"8.26%).":[150],"This":[151],"prespecified":[154],"10%":[155],"noninferiority":[156],"margin.":[157],"well":[160],"tolerated,":[161],"most":[163],"adverse":[164],"events":[165],"being":[166],"categorized":[167],"as":[168],"mild.":[169],"In":[170],"conclusion,":[171],"noninferior":[174],"3":[180],"clinical":[181],"trial":[182,221],"On":[194],"basis":[196],"these":[198],"results,":[199],"efficacious":[204],"pathogens.":[219],"(This":[220],"has":[222],"been":[223],"registered":[224],"ClinicalTrials.gov":[226],"under":[227],"identifier":[228],"NCT02607618.).":[229]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2018-03-29T00:00:00"}